Jivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week.
The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive officers. CEO Sidney Hopps filed the report, along with CFO Kenneth Templin.
Get the full story at our sister site, Drug Delivery Business News.